The Auburn University College of Veterinary Medicine's chapter of the Omega Tau Sigma professional fraternity recently contributed more than $ 2,932 raised through its benevolent fundraising efforts to
a cancer research program at the college.
«Black women have been noted to present [at a doctor's office] with later stage cancer, which has a worse outcome — and they don't always get adequate care,» says Ruth ORegan, MD, associate professor of hematology and oncology and director of the translational breast
cancer research program at Emory University's Winship Cancer Institute in Atlanta.
Funding for additional projects may be provided from institutional commitment and philanthropic funds from the Uterine
Cancer Research Program at MD Anderson.
Dr. Wolff is an Associate Professor of Oncology and member of the Breast
Cancer Research Program at The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
«We identified a number of new genes that are frequently mutated in CS,» said senior author Alessandro Santin, M.D., professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, and program leader of the gynecological
cancers research program at Smilow Cancer Hospital at Yale - New Haven and a member of Yale Cancer Center.
Not exact matches
Zach works full - time in the Extramural
Research Department
at the American
Cancer Society and teaches high school life sciences part - time in a hybrid education
program he co-founded in 2013.
At Nationwide Children's, we help kids everywhere and provide life - saving
research and care in
Cancer, NICU, The Heart Center, Muscular Dystrophy and all of our nationally ranked clinical
programs.
«Our findings suggest that teens and young adults who seek indoor tanning may be especially vulnerable to developing BCC, the most common form of skin
cancer, at a young age,» said lead author Professor Margaret Karagas, co-director of the Cancer Epidemiology and Chemopreventon Research Program at the Norris Cotton Cancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at Dart
cancer,
at a young age,» said lead author Professor Margaret Karagas, co-director of the
Cancer Epidemiology and Chemopreventon Research Program at the Norris Cotton Cancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at Dart
Cancer Epidemiology and Chemopreventon
Research Program at the Norris Cotton
Cancer Center and Director of the Children's Environmental Health and Disease Prevention Research Center at Dart
Cancer Center and Director of the Children's Environmental Health and Disease Prevention
Research Center
at Dartmouth.
«Because resource availability varies widely, both among and within countries, we need to adjust strategies to improve access to HPV vaccination everywhere,» said Silvia de Sanjosé, MD, PhD, co-chair of the Expert Panel that developed the guideline and head of the
Cancer Epidemiology
Research Program at Institut Català d'Oncologia in Barcelona, Spain.
This work was supported by the Carney Family Charitable Foundation, the National
Cancer Institute's SPORE in Breast
Cancer at Dana - Farber / Harvard
Cancer Center (grant P50CA168504), STIMIT Corporation, and the Claudia Adams Barr
Program for Innovative
Cancer Research.
At the Fred Hutchinson
Cancer Research Center (FHCRC), there has been a strong center - driven effort to provide resources for interdisciplinary research training, such as establishing the Joint Degree and Dual Mentor p
Research Center (FHCRC), there has been a strong center - driven effort to provide resources for interdisciplinary
research training, such as establishing the Joint Degree and Dual Mentor p
research training, such as establishing the Joint Degree and Dual Mentor
programs.
He holds the Canada
Research Chair in Stem Cell Biology and is Director of the
Cancer Stem Cell
Program at the Ontario Institute for
Cancer Research.
While pursuing her project on how environmental contaminants and oxidative stress cause lung
cancer, Gelhaus complemented her postdoctoral training by spending some time with other PIs
at Penn. «She has worked hard to develop skills that are independent of those available in my own laboratory while working on a project that is central to my
research program,» Blair writes in an e-mail to Science Careers.
Steven Narod, director of the Familial Breast
Cancer Research Unit
at Women's College
Research Institution in Toronto, believes that cost and not flawed computer
programs are to blame for undertesting.
Today, an article published in
Cancer Discovery by Manel Esteller, Director of the Epigenetics and
Cancer Biology
Program of Bellvitge Biomedical
Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics
at the University of Barcelona, explains that this RNA also has its own spelling and grammar, just like DNA.
«We are looking to optimize the combinations of targeted therapies and the scheduling of those therapies so we can improve tumor shrinkage and minimize potential toxicities for a patient,» said Andrew Aplin, PhD, Associate Director for Basic
Research and the
Program Leader for
Cancer Cell Biology and Signaling (CCBS) in the NCI - designated Sidney Kimmel
Cancer Center
at Jefferson Health.
Extending national breast
cancer screening
programs to women over the age of 70 does not result in a decrease in the numbers of
cancers detected
at advanced stages, according to new
research from The Netherlands.
Dr Gerrit - Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology
research group
at Leiden University Medical Centre (Leiden, The Netherlands), said: «For a screening
program to be effective, one would expect that the incidence of early stage breast
cancer would increase while the incidence of advanced stage
cancer would decrease because any
cancer would have been detected
at an earlier stage.
University of Calgary researchers including Luchman, Weiss and Dr. Greg Cairncross — director of SACRI, and leader of the Terry Fox
Research Institute (TFRI) «Therapeutic Targeting of Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliob
Research Institute (TFRI) «Therapeutic Targeting of Glioblastoma
research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliob
research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliobl
program at the university — are now working with
cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliobla
cancer researchers Dr. Warren Mason (Princess Margaret
Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliobla
Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug
Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with gliobl
Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblastoma.
Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology
program at Perlmutter
Cancer Center
at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology
at NYU School of Medicine, presented these findings April 16
at the American Association for
Cancer Research (AACR) Annual Meeting 2018 in Chicago.
In his day job,
at the University of Texas MD Anderson
Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mort
Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied
Research of Genitourinary
Cancers and executive director of the immunotherapy division of the Moon Shots
Program, a multidisciplinary effort tackling
cancer mort
cancer mortality.
Its founder, Allan Bradley, was
at the time based
at the M.D. Anderson
Cancer Research Center in Houston, Texas, and now heads the world's largest mouse genetics program at the Wellcome Trust Sanger Institute, which has a strong cancer comp
Cancer Research Center in Houston, Texas, and now heads the world's largest mouse genetics
program at the Wellcome Trust Sanger Institute, which has a strong
cancer comp
cancer component.
«The findings of both studies support a growing body of
research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both
research that suggests lifestyle interventions lower biomarkers associated with breast
cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both st
cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-
program leader of the
Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both st
Cancer Prevention and Control
Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both
Research Program at Yale
Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both st
Cancer Center, associate professor of Epidemiology
at Yale School of Public Health, and principal investigator on both studies.
«This is the first time that this specific protein - protein signaling complex has been identified in GBM, and it gives us a new potential target for drug development,» says Fisher, Thelma Newmeyer Corman Endowed Chair in
Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of t
Research and co-leader of the
Cancer Molecular Genetics
research program at VCU Massey, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of t
research program at VCU Massey, professor and chair of the Department of Human and Molecular Genetics
at the VCU School of Medicine, and director of the VIMM.
Based
at the
Cancer Research Institute in New York, Old is the director of the Cancer Vaccine Collaborative, an international program dedicated to fighting cancer from the insid
Cancer Research Institute in New York, Old is the director of the
Cancer Vaccine Collaborative, an international program dedicated to fighting cancer from the insid
Cancer Vaccine Collaborative, an international
program dedicated to fighting
cancer from the insid
cancer from the inside out.
Jean - Pierre Issa, MD, Director of the Fels Institute for
Cancer Research and Molecular Biology
at Temple University School of Medicine and co-Leader of the
Cancer Epigenetics
Program at the Fox Chase
Cancer Center is lead author of the study, which has been published August 19 in the journal, Lancet Oncology.
In these vesicles, we saw the EGFR and HER2 receptors being broken down, but we also saw our negative control receptor, c - MET,» said Dent, who is the Universal Corporation Chair in
Cancer Cell Signaling and a member of the
Cancer Cell Signaling
research program at Massey.
Reed is a member of the
Cancer Molecular Genetics
research program at VCU Massey
Cancer Center and an associate professor in the Department of Physics
at the VCU College of Humanities and Sciences.
«Pancreatic
cancer cells are deadly because they program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU La
cancer cells are deadly because they
program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU L
program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the
Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU La
Cancer Immunology
Program at Perlmutter and vice chair for research in the Department of Surgery at NYU L
Program at Perlmutter and vice chair for
research in the Department of Surgery
at NYU Langone.
This study was supported by Norma C. and Albert I. Geller via the Gynecological
Cancer Translation
Research Program at the Case Comprehensive
Cancer Center, and grants from The Mary Kay Foundation (to A.D. and R.X.), the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator award number DP2HD084068 (to R.X.), The National
Cancer Institute award number R011CA197780 - 01A1 (to A.D.), and The Young Scientist Foundation (A.D.).
The tech transfer internship
program at the University of Michigan is run by Elaine Brock, the director of the Medical School's Office of Technology Transfer and Corporate
Research, a lawyer who was also trained in health services administration; and assistant director Maria Sippola - Thiele, a former National
Cancer Institute postdoc who subsequently got her M.B.A. from the University of Michigan.
«We still have a long way to go and many challenges to overcome before we will have therapies that are ready for clinical use, but this is a significant first step in the process,» says Emdad, member of the
Cancer Molecular Genetics
research program at Massey, assistant professor in the VCU Department of Human and Molecular Genetics and member of the VIMM.
«As someone who
researches pancreatic
cancer, I think this discovery is significant because it defines mechanisms that lead to this cancer in ways that we didn't know about before,» says Firpo, who's also a member of the Pancreas Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer Inst
cancer, I think this discovery is significant because it defines mechanisms that lead to this
cancer in ways that we didn't know about before,» says Firpo, who's also a member of the Pancreas Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer Inst
cancer in ways that we didn't know about before,» says Firpo, who's also a member of the Pancreas
Cancer Research Program and Experimental Therapeutics Program at the University of Utah's Huntsman Cancer Inst
Cancer Research Program and Experimental Therapeutics
Program at the University of Utah's Huntsman
Cancer Inst
Cancer Institute.
The MD / PhD
program at UT Houston and the Anderson
Cancer Center was designed to train investigators who could better bridge the gap between basic science and clinical
research, and as an alternative to the traditional MSTP
program model.
«We challenged a current dogma in the field that emphasized PLK1's role in mitosis (cell division) as a primary mechanism for
cancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Med
cancer growth,» says Zheng Fu, Ph.D., lead investigator on the study, member of the
Cancer Molecular Genetics research program at VCU Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Med
Cancer Molecular Genetics
research program at VCU Massey
Cancer Center and assistant professor in the Department of Human and Molecular Genetics at the VCU School of Med
Cancer Center and assistant professor in the Department of Human and Molecular Genetics
at the VCU School of Medicine.
A different pathway is used to train students in the combined degree
program at the University of Texas Health Science Center
at Houston (UT Houston) and the University of Texas M. D. Anderson
Cancer Center, where the goal is to produce physician - scientists who will pursue careers in clinical
research.
The session featured Sadis Matalon, associate dean of the Office of Postdoctoral Education
at the University of Alabama, Birmingham (UAB); Jonathan Wiest, associate director for Training and Education
at the National
Cancer Institute's (NCI?s) Center for
Cancer Research (CCR); and Mary Anne With, director of Institutional Oversight for the Postdoctoral
Program at Los Alamos National Laboratory (LANL).
«Because of relatively low survival rates and their advancing age, these patients tend to be poor candidates for aggressive therapies, like a bone marrow transplant,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, chief of the Division of Regenerative Medicine
at UC San Diego School of Medicine and director of the Stem Cell
Research Program at Moores
Cancer Center.
«Most of the scientific community in Spain is looking with sadness to the current events,» Manel Esteller, director of the
Cancer Epigenetics and Biology
Program at the Bellvitge Biomedical
Research Institute in Barcelona, writes in an e-mail to ScienceInsider.
In the early 1990s, the group lobbied to create a Department of Defense breast
cancer research program now funded
at $ 150 million a year.
Today, an article published in Cell by Manel Esteller, director of the Epigenetics and
Cancer Biology
Program of the Bellvitge Biomedical
Research Institute (IDIBELL), ICREA researcher and Professor of Genetics
at the University of Barcelona, describes the possible existence of a sixth DNA base, the methyl - adenine (mA), which also help determine the epigenome and would therefore be key in the life of the cells.
Today, an article published in the prestigious journal Molecular Cell by Manel Esteller, Director of Epigenetics and
Cancer Biology
Program of the Bellvitge Biomedical
Research Institute (IDIBELL), ICREA researcher and Professor of Genetics
at the University of Barcelona, provides a twist over this mystery.
«Our
research shows that the protein GSK3 plays a crucial role in helping B cells meet the energy needs of their distinct states,» says Robert Rickert, Ph.D., director of the Tumor Microenvironment and
Cancer Immunology
Program at Sanford Burnham Prebys Medical Discovery Institute (SBP).
«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a hematologist - oncologist in the Bone Marrow Transplant
Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Me
Program and member of the Developmental Therapeutics
research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Me
program at VCU Massey
Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care
at the VCU School of Medicine.
The findings will be presented as part of a poster presentation by members of the Rutgers
Cancer Institute Precision Medicine
Program at the Annual Meeting of the American Association for
Cancer Research (AACR) being held in New Orleans next month.
«We are
at a point in our
research where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to define its safety through toxicology and pharmacology studies,» says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular M
research where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to define its safety through toxicology and pharmacology studies,» says Fisher, Thelma Newmeyer Corman Endowed Chair in
Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular M
Research and co-leader of the
Cancer Molecular Genetics
research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular M
research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine.
Co-senior author on the
Cancer Cell study, Dr. Matthew Wilkerson, associate professor and Bioinformatics Director of The American Genome Center and the Collaborative Health Initiative
Research Program at the Uniformed Services University.
The director of the
Program Epigenetics and
Cancer Biology (PEBC) at Bellvitge Biomedical Research Instiute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, Manel Esteller, has established the epigenetic patterns of breast cancer and also its clinical consequ
Cancer Biology (PEBC)
at Bellvitge Biomedical
Research Instiute (IDIBELL), Professor of Genetics
at the University of Barcelona and ICREA researcher, Manel Esteller, has established the epigenetic patterns of breast
cancer and also its clinical consequ
cancer and also its clinical consequences.
This complexity contributes to its aggressive nature and resistance to conventional therapies such as chemotherapy and radiation therapy,» says Fisher, Thelma Newmeyer Corman Endowed Chair in
Cancer Research and co-leader of the Cancer Molecular Genetics research program at Massey Cancer Center, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of t
Research and co-leader of the
Cancer Molecular Genetics
research program at Massey Cancer Center, professor and chair of the Department of Human and Molecular Genetics at the VCU School of Medicine, and director of t
research program at Massey
Cancer Center, professor and chair of the Department of Human and Molecular Genetics
at the VCU School of Medicine, and director of the VIMM.
This
research was made possible by patients who were treated
at Moffitt and generously donated blood and tissue samples to the Total
Cancer Care ®
Program and was supported in part by grants from the American
Cancer Society (93-032-16) and the National
Cancer Institute.